# Dendritic Cell Vaccine for Patients With Brain Tumors

> **NCT01204684** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Glioma
- Anaplastic Astrocytoma
- Anaplastic Astro-oligodendroglioma
- Glioblastoma

## Interventions

- **BIOLOGICAL:** autologous tumor lysate-pulsed DC vaccination
- **BIOLOGICAL:** Tumor lysate-pulsed DC vaccination+0.2% resiquimod
- **BIOLOGICAL:** Tumor-lysate pulsed DC vaccination +adjuvant polyICLC

## Key facts

- **NCT ID:** NCT01204684
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-08
- **Primary completion:** 2024-08-21
- **Final completion:** 2024-08-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204684, "Dendritic Cell Vaccine for Patients With Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01204684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*